Open AccessAbstract 6109: Enzalutamide treatment of patient derived bone metastatic prostate cancer xenograft models implanted in the bone resulted in durable progression to castration resistant prostate cancer (CRPC)
Author(s) -
Christina Jamieson,
Michelle Muldong,
SangHee Lee,
C. Wu,
Danielle Burner,
Theresa R. Mendoza,
Catalina Arreola,
Abril Zuniga,
Nicholas A. Cacalano,
Catriona Jamieson,
Christopher J. Kane,
Anna Kulidjian
Publication year - 2020
Publication title -
cancer research
Language(s) - English
Resource type - Conference proceedings
SCImago Journal Rank - 1.055
H-Index - 84
eISSN - 1538-7445
pISSN - 0008-5472
DOI - 10.1158/1538-7445.am2020-6109
Subject(s) - enzalutamide , prostate cancer , medicine , bone metastasis , metastasis , cancer research , bicalutamide , androgen deprivation therapy , cabazitaxel , cancer , androgen receptor , prostate , oncology